Agilent Technologies, Inc. · NYSE:A
Agilent Technologies — Q3 2021 Earnings Presentation
8 slides from Agilent Technologies's earnings presentation, Aug 17, 2021
Slide 1: Agilent Technologies Q3'21 Results Presentation
Agilent Technologies Q3’21 Results Presentation
Slide 2: Safe Harbor
Safe Harbor These presentations contain forward-looking statements (including, without limitation, information, and future guidance on the company’s goals, priorities, revenue, revenue growth, earnings per share, operating margin, operating cash flow, capital expenditures, capital allocation, growth
Slide 3: Agilent Results Q3'21
Agilent Results Q3'21 Scale and leading technology across Analytical Laboratories and Dx & Clinical markets Q3'21 Financial Metrics Q3’21 Highlights • Revenues: $1.59B, +20.8% y/y • Growth was broad-based across all end markets and core(1)(2),+25.8% reported (+4.5% FX, regions led by strength in Pha
Slide 4: Life Sciences & Applied Markets Group (LSAG)
Life Sciences & Applied Markets Group (LSAG) • Q3 core revenue performance reflected strength in Instrumentation and Informatics key end markets led by Pharma and Chemical & for Analytical Laboratories Energy. Momentum across all platforms led by LC, Cell Analysis, and Spectroscopy. • Announced the
Slide 5: Agilent Cross Lab Group (ACG)
Agilent Cross Lab Group (ACG) Analytical Laboratory • Mid-teens revenue growth in Q3 was regionally Consumables and Services broad-based and well balanced between services and consumables. The business benefitted from increased activity in customer labs driving demand for both goods and services. •
Slide 6: Diagnostics and Genomics Group (DGG)
Diagnostics and Genomics Group (DGG) • Q3 core revenue growth was broad-based across Pathology, Genomics, and Nucleic Acid Manufacturing the entire portfolio – led by exceptional results in NASD, strong demand for genomics instrumentation and consumables, and continued recovery in cancer diagnostics
Slide 7: Growth in a $58B Market – Q3'21 Results by End Market
Growth in a $58B Market – Q3'21 Results by End Market Continued momentum in Pharma and Food; Emerging recovery in Dx, A&G, and C&E Analytical Laboratory End Markets Q3'21 revenues: +20% y/y on core(2) basis Pharma & Biotech: Up 27% with strong double-digit growth across all geographies and busin
Slide 8: Q4'21 and FY21 Guidance and Forward-looking Considerations
Q4’21 and FY21 Guidance and Forward-looking Considerations Based on July 31, 2021 Exchange Rates Q4’21 Guidance (1) FY21 Guidance (1) Low End High End Low End High End Net Revenue ($M) $1,630 $1,660 Net Revenue ($M) $6,290 $6,320 Y/Y Core Revenue Growth (2) 8.5% 10.0% Y/Y Core Revenue Growth (2) 14.